Systemic Lupus Erythematosus Journal Articles

• Safety of IV Golimumab in RA, PsA, and AS A pooled analysis of data from three trials provides insight into the safety profile of IV golimumab for the treatment of these rheumatologic conditions.
  Arthritis Research & Therapy, May 18, 2022
• Non-Pharmacological Treatment of Systemic Sclerosis Symptoms When it comes to the treatment of these symptoms in patients with systemic sclerosis, what are the non-pharmacologic options? This article provides evidence-based recommendations.
  Rheumatology, May 18, 2022
• Advances in the Clinical Use of Hydroxychloroquine Levels What role could the assessment of hydroxychloroquine levels have in the management of patients with lupus?
  Current Opinion in Rheumatology, May 05, 2022
• Suggestions for Successful SGLT2i Use in Glomerular Disease Findings from recent trials further support the benefits of SGLT2 inhibitors in the management of glomerular disease. This review provides guidance for successful implementation.
  Current Opinion in Nephrology and Hypertension, May 05, 2022
• Rheumatoid Factor Positivity in ANCA-Associated Vasculitis What is the role of rheumatoid factor positivity in ANCA-associated vasculitis? A new study investigates.
  Rheumatology, May 04, 2022
• Assessing Long-Term Outcomes in Breast Implant Illness The term 'breast implant illness' has raised questions about the safety of breast implants, but there is still much to be learned about this condition.
  Plastic and Reconstructive Surgery, April 20, 2022
• Third mRNA Vaccine in Preventing COVID-19 Hospitalization According to this CDC report, a third dose of an mRNA COVID-19 vaccine significantly increases effectiveness against hospitalization among adults without and with immunocompromising conditions.
  Morbidity & Mortality Weekly Report, April 18, 2022
• Effect of Glucocorticoid Dose During Pregnancy in SLE Glucocorticoid dose for SLE during pregnancy may be associated with adverse outcomes. Should a lower dose be considered?
  Arthritis Research & Therapy, March 23, 2022
• Janus Kinase and Tyrosine Kinase Inhibitors in Dermatology This review details the mechanism of action of JAK inhibitors and assesses their efficacy and safety in the treatment of a wide variety of dermatological conditions.
  Skin Therapy Letter, March 17, 2022
• Rheumatic Disease Flare-Up After SARS-CoV-2 mRNA Vaccine A new study finds a low incidence of disease flare-up after mRNA SARS-CoV-2 vaccines among rheumatic musculoskeletal disease patients.
  Arthritis Research & Therapy, March 16, 2022
• The Epidemiology of Alopecia Areata This study elucidates the epidemiology of alopecia areata, focusing on incidence, demographics and patterns of healthcare utilization.
  The British Journal of Dermatology, March 14, 2022
• Prioritizing Referrals of Individuals At-Risk of RA When should patients with suspected inflammatory arthritis be referred to a rheumatologist? This article provides some guidance.
  Arthritis Research & Therapy, March 09, 2022
• Immunosuppression Withdrawal After Lupus Nephritis Remission In lupus nephritis patients in remission, could immunosuppressive therapy be safely withdrawn?
  Rheumatology, March 03, 2022
• Neuropsychiatric Manifestations of Thyroid Disease Learn more about the cognitive and psychiatric disorders associated with thyroid dysfunction and the pathophysiology behind these manifestations.
  Journal of the Endocrine Society, March 01, 2022
• Safety of Recombinant Zoster Vaccine in Rheumatology Patients Is the recombinant zoster vaccine safe to use in rheumatology patients taking immunosuppressive medications?
  Southern Medical Journal, February 23, 2022
• Histopathology in Transbronchial Biopsy, Autopsy in COVID-19 This comparison of pre- and postmortem pathological findings in paired lung biopsies and autopsy samples in patients with COVID-19 elucidates early pathologic changes and progression of disease.
  American Journal of Clinical Pathology, February 11, 2022
• Psoriasis-related Treatment, Hospitalization Due to COVID-19 Have systemic treatments for psoriasis been associated with an increased risk of hospitalization or in-hospital mortality due to COVID-19?
  The British Journal of Dermatology, February 07, 2022
• Risk of VTE Associated With Tofacitinib in Patients With RA Does tofacitinib treatment increase the risk for venous thromboembolism in patients with rheumatoid arthritis?
  Rheumatology, February 02, 2022
• mRNA COVID-19 Vaccine Effectiveness in the Immunocompromised This CDC report reveals that mRNA COVID-19 vaccines are less effective in immunocompromised persons, supporting the recommendation for administration of a third dose of mRNA vaccine in this group.
  Morbidity & Mortality Weekly Report, January 26, 2022
• Chilblain-like Lesions During the COVID-19 Outbreak This study aimed to elucidate the underlying pathophysiology of chilblain-like lesions which some patients developed during the COVID-19 pandemic.
  The British Journal of Dermatology, January 18, 2022